Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Index Biosystems Inc. maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. Currently, the company has 1 pending office action. This pending matter is located in 1 distinct art unit, indicating a specific focus within these biological technical categories. This concentration indicates a strategic emphasis on a particular technical niche within the Biotechnology & Pharmaceuticals sector.
The examination process is overseen by 1 distinct examiner. LUO, JAMMY NMN is the busiest examiner for the portfolio, handling 1 pending office action. The data shows that there is no distribution of the workload across multiple examiners at this time. The use of 1 distinct examiner suggests a centralized review process where all communication is directed through this official, which simplifies the management of the portfolio.
With 1 pending office action and 1 distinct examiner, the prosecution environment is very narrow. Practitioners can see that the 1 distinct art unit involved is the only area of active prosecution for Index Biosystems Inc. Since LUO, JAMMY NMN handles 1 pending office action, the outcome depends on this individual's interpretation of the claims.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LUO, JAMMY NMN | 1 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17780030 | METHODS AND COMPOSITIONS FOR PROVIDING IDENTIFICATION AND/OR TRACEABILITY OF BIOLOGICAL MATERIAL | LUO, JAMMY NMN | — |
| Art Unit | Apps |
|---|---|
| 1686 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17780030 | METHODS AND COMPOSITIONS FOR PROVIDING IDENTIFICATION AND/OR TRACEABILITY OF BIOLOGICAL MATERIAL | LUO, JAMMY NMN | 1686 | §101§103§112 | Non-Final OA | — | Pending | May 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIndex Biosystems Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jammy Nmn Luo has the most, with 1 of Index Biosystems Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
